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Background. The impact of human genetic background on low-trauma fracture (LTF) risk has not been evaluated in the context
of human immunodeﬁciency virus (HIV) and clinical LTF risk factors.
Methods. In the general population, 6 common single-nucleotide polymorphisms (SNPs) associate with LTF through genome-
wide association study. Using genome-wide SNP arrays and imputation, we genotyped these SNPs in HIV-positive, white Swiss HIV
Cohort Study participants. We included 103 individuals with a ﬁrst, physician-validated LTF and 206 controls matched on gender,
whose duration of observation and whose antiretroviral therapy start dates were similar using incidence density sampling. Analyses
of nongenetic LTF risk factors were based on 158 cases and 788 controls.
Results. A genetic risk score built from the 6 LTF-associated SNPs did not associate with LTF risk, in both models including and
not including parental hip fracture history. The contribution of clinical LTF risk factors was limited in our dataset.
Conclusions. Genetic LTF markers with a modest effect size in the general population do not improve fracture prediction in
persons with HIV, in whom clinical LTF risk factors are prevalent in both cases and controls.
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Bone health is a major long-term concern in human immuno-
deﬁciency virus (HIV)-positive persons. Large observational
studies have documented increased rates of osteoporosis and
fractures in HIV-positive individuals compared with the general
population. The pathogenesis of bone disease during HIV infec-
tion is incompletely deﬁned; a high prevalence of smoking and
substance use, low body weight, hepatitis C coinfection, vitamin
D deﬁciency, as well as the effects of HIV itself, HIV-associated
inﬂammation, and certain antiretroviral therapy (ART) agents
have been implicated [1–6].
Bone mineral density and low-trauma fractures (LTFs) have a
strong hereditary component [7, 8]. Genome-wide association
studies (GWAS) have identiﬁed 6 common genetic variants
that reproducibly contribute to either osteoporosis or fracture
risk in the general population [9]. The primary aim of the pre-
sent study was to quantitate the contribution of these gene var-
iants to the risk of LTF in HIV-positive participants enrolled in
the Swiss HIV Cohort Study (SHCS), in the context of clinical,
HIV-related, and antiretroviral factors contributing to LTF risk.
A secondary aim was the assessment of 61 single-nucleotide
polymorphisms (SNPs) associated with bone mineral density
in the reference paper [9]. We included only LTF that were val-
idated in writing by the treating HIV physician. To our knowl-
edge, this represents the ﬁrst genetics-fracture study undertaken
in HIV-positive persons.
METHODS
Study Population, Inclusion, and Exclusion Criteria
Eligible participants included HIV-positive persons enrolled in
the SHCS (www.shcs.ch) [10], with ≥2 years follow-up after
January 1, 1998. The study was approved by the local ethics
committees. Participants provided written informed consent
for genetic testing. Low-trauma fracture cases included all
SHCS participants who developed a LTF during the study peri-
od, which was from SHCS enrollment until December 31, 2014.
For participants with >1 LTF event, only the ﬁrst event was in-
cluded. Eligible participants who remained fracture-free during
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the study period were potential controls. Because most previous
fracture GWAS in the general population were conducted in
populations of European descent [9], the present report is re-
stricted to participants of European descent.
Low-Trauma Fractures
The treating HIV physician conﬁrmed in writing the presence,
date, body site, and low trauma nature of all fractures. Low-
trauma fractures were deﬁned as resulting from a fall at standing
height or less, at walking speed or less, and at age ≥18. For
asymptomatic vertebral fractures detected by radiologic imag-
ing, diagnosis relied on the attending radiologist’s report and
the imaging date was used. Fractures of the skull, cervical
spine, ﬁngers, and toes were excluded because these are typically
considered traumatic in nature. Fractures occurring in patients
with a history of malignancy were excluded to avoid including
pathological fractures. The annualized LTF rate in the SHCS
was calculated as the number of LTFs divided by the number
of person-years of follow-up.
Case-Control Matching: Nongenetic Analyses
Controls were matched to cases by gender, and using incidence
density sampling [11], on ART start and stop dates, which are
recorded in the SHCS database. Patients were eligible as con-
trols if their ART start date was within 1 year of the case’s
and if they were still receiving ART at the time of the case’s frac-
ture. All eligible controls were identiﬁed for each case, 5 of
whom were selected at random (if <5 controls were available,
all were selected). Any control matched to a case was removed
from the list of eligible controls. Cases with no matching con-
trols (n = 9) were dropped, and participants with unconﬁrmed
LTF were excluded from the set of eligible controls. The expect-
ed effect of incidence density sampling is to correct for differ-
ences in ART compounds in use at different times during the
study period, a correction that would not be achieved if match-
ing were based only on ART duration. To ensure similar dura-
tion of observation, follow-up ended on the date of the fracture
of the corresponding case for both cases and controls.
Case-Control Matching: Genetic Analyses
For the analyses that include genotype data (GWAS and logistic
regression including genetic risk scores), the patient set was pro-
duced with the same procedure as the nongenetic analyses (see
above), with the following differences: (1) only patients with
available deoxyribonucleic acid or genome-wide genotyping
data were included; (2) the “difference in ART start date” crite-
rion was relaxed from 1 year to 2 years; and (3) up to 2 controls
(instead of 5) were allowed per case (this has the effect of low-
ering the rate at which eligible controls are exhausted, thus low-
ering the probability of a case being dropped for lack of
matching controls).
Genotyping: Quality Control
Deoxyribonucleic acid obtained from peripheral blood mono-
nuclear cells was genotyped using the Human OmniExpress
24 array (n = 100 cases) or in the context of previous GWAS
(n = 3 cases and 206 controls) [12–14].Missing genotype impu-
tation was performed with Mach [15, 16] and minimac [17, 18]
using 1000 Genomes Phase 3 population data as reference hap-
lotypes, resulting in a total of >6 million SNPs available for anal-
ysis. Imputed markers were ﬁltered on minor allele frequency
(excluded if <0.01) and imputation quality using Mach’s report-
ed r-squared measure (excluded if <0.3). Participants were ﬁl-
tered based on cryptic relatedness (dropped if identity by state
>0.12). We used a modiﬁed Eigenstrat approach to control for
the possibility of spurious associations resulting from residual
population stratiﬁcation [19]. This method derives the principal
components of the correlations among common (minor-allele
frequency, >5%) gene variants, which reﬂect population ances-
try, and corrects for those correlations in the subsequent asso-
ciation tests by integrating the coordinates of the signiﬁcant
principal component axes as covariates (Eigenstrat covariates)
in the models.
Nongenetic Low-Trauma Fractures Risk Factors
We tested LTF associations of nongenetic factors by conditional
logistic regression, both univariable or multivariable. Analyses
were done using R [20] and PLINK [21]. The variables included
in the model were deﬁned a priori, based on their contribution
to LTF in large observational studies [1–3, 5, 6].All variables en-
tered the model as the information available closest to the frac-
ture date of the corresponding case. Human immunodeﬁciency
virus-related variables included CD4 count, CD4 nadir, cumu-
lative exposure to tenofovir disoproxil fumarate, protease inhib-
itor use with/without ritonavir, and hepatitis C virus (HCV)
coinfection, deﬁned as detectable HCV ribonucleic acid at
least once during SHCS follow-up. Other variables were height,
weight, alcohol consumption (≥3 standard units daily con-
sumption vs less [22]), smoking (current/ever smoking vs
never [23]), injection drug use, corticosteroid use (ever used
oral prednisone 5 mg equivalent for ≥3 months [24]), and pa-
rental hip fracture history [25]. The variables found to be asso-
ciated with LTF risk in the multivariable model were retained,
together with the genetic risk score quartile, to form the genetic
model.
Genetic Association Analyses
We built an a priori deﬁned genetic risk score using 6 SNPs
(or a proxy with r2 > 0.8) with known fracture association at
GWAS-wide signiﬁcant P < 5 × 10−8 in the reference paper [9]
(Supplementary Table 1). Based on these SNPs we applied the
following: (1) an additive genetic score (number of risk alleles;
heterozygous = 1, homozygous = 2; ie, scores ranged from
0 to 12, with higher scores indicating increased LTF risk); and
(2) an additive weighted genetic score that takes into account
the effect size reported in the reference paper [9]. For a SNP
with, eg, a fracture odds ratio (OR) of 1.15, reference allele = 0,
heterozygous = 0.15, and homozygous risk allele = 0.3. The
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numbers obtained for each SNP were added to create an indi-
vidual weighted genetic risk score, and study participants were
divided into 4 genetic score quartiles.
Exploratory Genetic Association Analyses
The study was designed for replication of the 6 SNPs identiﬁed
in GWAS in the general population [9]. However, because
GWAS arrays were used for genotyping of all study participants,
good practice calls for reporting genome-wide results. Thus,
ﬁrst, all genotyped or imputed SNPs were separately tested for
association with LTF by logistic regression. We used Bonferroni
adjustment, taking into account the number of tested SNPs, to
correct for multiple testing. Second, we considered separately
the 61 SNPs mapping to genes associated with bone mineral
density in the reference paper [9]; 3 SNPs were not interrogated
because they were neither present in the array nor reliably im-
puted. The distribution of association P values was compared
between these groups and all other SNPs genotyped on the
array using the 2-sample Kolmogorov-Smirnov test.
RESULTS
Participants: Fractures
Between January 1, 1998 and December 31, 2014, 158 con-
ﬁrmed LTFs were recorded in SHCS participants during
116 994 person-years of follow-up, for a LTF rate of 1.35 per
1000 person-years. After incidence density sampling, the
study population for the analysis of nongenetic LTF risk factors
included 158 cases and 788 clinical controls (cumulative follow-
up, 16 278 person-years). Low-trauma fracture sites included
spine (n = 70), femoral neck (n = 28), foot (without toes;
n = 25), ankle (n = 17), humerus (n = 11), wrist (n = 10), ribs
(n = 20), and other sites (n = 15). The characteristics of partic-
ipants are shown in Table 1. The median age at ﬁrst LTF was 52
years, and 34% of cases were women.
Associations Between Nongenetic Factors and Low-Trauma Fractures
In univariable analysis, LTF risk was associated with age, height,
and corticosteroids exposure ≥3 months, and trends were noted
for smoking and parental history of hip fracture (Table 2). In
multivariable analysis, LTF risk was associated with height, cor-
ticosteroids, and smoking. Weight, CD4 nadir, HCV coinfec-
tion, alcohol, injection drug use, cumulative exposure to
tenofovir disoproxil fumarate, and protease inhibitors (both
with and without ritonavir) were not associated with LTF risk.
No Association Between Genetic Risk Score and Low-Trauma Fractures
The study population for genetic analyses included 103 cases
and 206 controls. In the multivariable model that included
genetic background, the additive genetic score was not asso-
ciated with LTF. Odds ratios were 0.11 (95% conﬁdence in-
terval [CI], 0.01–1.57), 0.20 (95% CI, 0.01–3.25), and 0.42
(95% CI, 0.03–5.22), respectively, for the second, third, and
fourth genetic score quartiles (most unfavorable genetic back-
ground), compared with the ﬁrst quartile (most favorable genetic
background). In this full model with genetics, age (OR, 1.00;
95% CI, 0.91–1.09), height (OR, 1.00; 95% CI, 0.89–1.13),
smoking (OR, 1.06; 95% CI, 0.19–6.00), or corticosteroid expo-
sure (OR, 0.67; 95% CI, 0.07–6.66) did not contribute to LTF
risk either (all P > .05). Results were similar when a weighted ge-
netic score was applied (data not shown). Removing parental
hip fracture history did not change the estimates for the genetic
score (Table 3).
Vertebral Versus Nonvertebral Fractures
We also ran the same models considering vertebral or nonver-
tebral fractures separately (Supplementary Tables 2 and 3). We
did not observe any association between genetic score and ver-
tebral or nonvertebral fractures.
Exploratory Genome-Wide Analyses
As expected, we did not observe any association between
human genetic variants and LFT in a genome-wide SNP anal-
ysis (Supplementary Figure 1). The 61 SNPs mapping to genes
associated with bone mineral density in the reference paper [9]
were also not associated with LTF risk (data not shown).
Table 1. Characteristics of the Cases and Controlsa
Cases
(n = 158)
Controls
(n = 788)
Male genderb, n (%) 104 (66) 520 (66)
Age (years), median (IQR) 52 (46–60) 49 (45–54)
Presumed mode of HIV transmission, n (%)
Heterosexual 55 (34.8) 180 (22.8)
MSM 48 (30.4) 302 (38.5)
IDU 46 (29.1) 288 (36.6)
other/unknown 9 (5.6) 18 (2.3)
Smoking, n (%)
Never 58 (37) 184 (23)
Past 26 (16) 157 (20)
Current 74 (47) 447 (57)
pack-years, median (IQR) 9 (0–20) 13 (0–20)
Alcohol >3 units per day, n (%) 77 (51) 392 (49)
Injection drug use, n (%) 46 (29) 288 (37)
Weight (kg), median (IQR) 67.5 (59.3–75.3) 68.2 (60.3–77)
Height (cm), median (IQR) 171 (164.2–175) 173 (167–179)
Hepatitis C coinfection, n (%) 42 (26.6) 231 (29.3)
Parent hip fracture, n (%) 35 (22.2) 129 (16.4)
Corticosteroid exposure ≥3 mo, n (%) 17 (11) 25 (3)
Duration of tenofovir disoproxil
fumarate treatment (years),
median (range)
2.1 (0–9.3) 2.7 (0–9.5)
Duration of protease inhibitor treatment (years), median (range)
with ritonavir 0.9 (0–14.8) 0.8 (0–15.1)
without ritonavir 4.1 (0–14.9) 3.2 (0–15.7)
CD4+ T-cell count (cells/μL)
median (range) 442 (27–1943) 512 (5–1888)
nadir (range) 119 (0–740) 141 (0–1075)
Abbreviations: HIV, human immunodeficiency virus; IDU, injection drug use; IQR,
interquartile range; MSM, men who have sex with men.
a Data are no. (%) of participants, unless otherwise indicated. For cases and controls, values
refer to those closest to the fracture date of the corresponding case.
b Controls were matched to cases on gender.
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DISCUSSSION
Our study, to our knowledge, represents a ﬁrst attempt to assess
the contribution of human genetic variation to LTF in HIV-
positive persons. A genetic risk score, which was deﬁned a priori
and captures the joint effect of 6 common SNPs with established
LTF association in GWAS in the general population [9], had a
negligible impact on LTF risk when considered in the context
of established demographic, clinical, andHIV-related risk factors.
Possible explanations for this include the relatively young age of
our HIV-positive patients and the smaller proportion of women
(approximately one third), compared with the reference paper
(approximately two thirds) [9].
Our negative genetic results seem robust; ﬁrst, we restricted
the analysis to SNPs with established LTF association [9]; second,
all SNPs were analyzed jointly, thereby avoiding false-positive re-
sults typically derived from candidate gene studies [26]; third, we
performed rigorous quality control of the genotyping data, ex-
cluding population outliers and correcting for residual popula-
tion stratiﬁcation. Fourth, the genetic score did not capture the
established effect of family history; this observation cannot be
explained by overﬁtting, because removing family history
from the model did not signiﬁcantly change the genetic results.
Even though the SHCS population is aging and includes
>9000 patients under active follow-up, a limited number of par-
ticipants have experienced LTF. Therefore, our study was limited
by sample size, in contrast to our previous genetic studies of dys-
lipidemia and diabetes mellitus in HIV in which similar num-
bers of cases allowed us to capture the effect of common SNPs
[27, 28]. Thus, a larger study might have found genetic associa-
tions. Because demonstration of the modest effect size of the
SNPs assessed in the genetic-LTF reference study in the general
population required meta-analysis including >130 000 persons
[9], longer follow-up and larger studies in aging HIV-positive
populations are important. Our exploratory, genome-wide anal-
yses did not provide any novel insight into the genetics of LTF.
This was expected, because the study was designed to assess
SNPs with validated LTF association and was not powered for
genome-wide discovery of novel variants. Additional limitations
include the lack of information on bone mineral density, diet,
vitamin D serum levels, physical activity, menopause status, vi-
tamin D supplements, and non-HIV medications other than
corticosteroids in our dataset. Finally, no lateral spine x-rays
were obtained, which have revealed a signiﬁcant prevalence of
vertebral fractures in HIV-positive persons in Italy [29].
Table 2. Contribution of Nongenetic Factors to Risk of Low-trauma Fractures in Univariable and Multivariable Analyses, Odds Ratio (95% Confidence
Interval)
Variable Univariable Analysis P Value
Multivariable Analysis
Without Genetic Background P Value
Age, per additional year 1.04 (1.02–1.06) <.01 1.02 (1.00–1.04) .06
Current/past smoking 0.98 (0.97–1.00) .07 0.58 (0.38–0.90) .02
≥3 units alcohol/day 1.01 (0.99–1.02) .38 1.11 (0.77–1.62) .57
Weight, per additional kg 0.99 (0.98–1.04) .15 1.00 (0.98–1.01) .81
Height, per additional cm 0.94 (0.91–0.96) <.01 0.95 (0.92–0.98) <.01
Hepatitis C coinfection 0.86 (0.58–1.29) .49 1.16 (0.68–1.96) .59
Injection drug use 0.68 (0.46–1.01) .06 0.86 (0.49–1.52) .60
CD4 nadir 1.00 (1.00–1.00) .95 1.00 (1.00–1.00) .26
Cumulative tenofovir exposure, per additional year 0.97 (0.90–1.04) .35 0.97 (0.90–1.05) .44
Protease inhibitor (with ritonavir) exposure, per additional year 1.01 (0.95–1.07) .76 1.04 (0.96–1.12) .35
Protease inhibitor (without ritonavir) exposure, per additional year 1.04 (0.98–1.09) .20 1.05 (0.99–1.12) .13
Parental history of hip fracture 1.46 (0.96–2.23) .08 1.35 (0.84–2.14) .21
Corticosteroid exposure ≥3 mo 4.15 (2.08–8.24) <.01 3.12 (1.48–6.58) <.01
a Current or past smoking vs never smoking.
b ≥3 units alcohol/day vs less.
Table 3. Odds Ratio for Low-Trauma Fracture According to Genetic Risk Score Quartile, Multivariable Models With and Without Parental Hip Fracture
Historya
Genetic Risk Score Quartile
Model With Parental
History of Hip Fracture P Value
Model Without Parental
History of Hip Fracture P Value
Genetic score quartile 2 vs quartile 1 0.12 (0.01–1.63) .11 0.12 (0.01–1.57) .11
Genetic score quartile 3 vs quartile 1 0.21 (0.12–3.49) .28 0.20 (0.01–3.25) .26
Genetic score quartile 4 vs quartile 1 0.43 (0.03–5.61) .36 0.42 (0.03–5.22) .50
a Data in parentheses are 95% confidence intervals.
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The prevalence of several clinical LTF risk factors noted in
previous studies in HIV [3, 6, 30] was similar in cases and
controls in our dataset and did not contribute to increased
LTF risk, including smoking, injection drug use, and HCV
coinfection. Indeed, the prevalence of current smoking,
past smoking, and the number of pack-years was each greater
in controls than in cases, resulting in lower LTF ORs in
smokers than in nonsmokers. This most likely is a chance
ﬁnding given the robust association of smoking with LTF
in large-scale meta-analysis in the general population [23].
The duration of exposure to tenofovir and protease inhibi-
tors did not contribute to LTF risk. This was also in contrast
to some large-scale analyses in HIV-positive populations [5]
and likely, at least in part, was because we selected only con-
trols who started ART contemporarily with corresponding
cases, and because follow-up was censored at the fracture
date in both controls and corresponding cases, ensuring sim-
ilar time under observation (including similar duration of
ART exposure).
Strengths of this study are the inclusion of all LTFs that oc-
curred in a large, well established, observational HIV study dur-
ing a 17-year period. All fractures were conﬁrmed, and their low
trauma nature ascertained in writing by the treating physician
using a standardized deﬁnition, thereby overcoming constraints
of registry-based studies [3, 5], and perhaps resulting in lower
LTF rates in the SHCS (1.35 LTF per 1000 person-years) than
in, eg, the US Veterans Aging Cohort Study (2.6 per 1000 per-
son-years) [6] and in the Women’s Interagency HIV Study (5.6
per 1000 person-years) [31].
CONCLUSIONS
In summary, our ﬁndings, based on the available, limited num-
ber of LTFs that have been recorded in the SHCS, suggest that
genetic testing is presently not a useful predictor or monitoring
tool for bone health in HIV.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Diseases
online (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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